Back to Search
Start Over
Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers
- Source :
- iScience. 25(9)
- Publication Year :
- 2022
-
Abstract
- Allo-HSCT is a curative therapy for hematologic malignancies owing to GvL effect mediated by alloreactive T cells; however, the same T cells also mediate GvHD, a severe side effect limiting the widespread application of allo-HSCT in clinics. Invariant natural killer T (iNKT) cells can ameliorate GvHD while preserving GvL effect, but the clinical application of these cells is restricted by their scarcity. Here, we report the successful generation of third-party HSC-engineered human iNKT (
- Subjects :
- Multidisciplinary
Subjects
Details
- ISSN :
- 25890042
- Volume :
- 25
- Issue :
- 9
- Database :
- OpenAIRE
- Journal :
- iScience
- Accession number :
- edsair.doi.dedup.....f91f7ef9a40676db22b48f87a8f1ea4e